{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:00:39Z","timestamp":1782493239362,"version":"3.54.5"},"reference-count":17,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211026"],"award-info":[{"award-number":["BK20211026"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical scientific research project approved by Jiangsu Provincial Health Commission","award":["M2021045"],"award-info":[{"award-number":["M2021045"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2023,2,22]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Preferentially expressed antigen in melanoma (PRAME) recently is a reliable immunohistochemistry (IHC) marker for distinguishing melanoma from other lesions. However, there are few articles focused on PRAME use in acral malignant melanoma, the most common type in Asians. This study investigated PRAME IHC expression in a large series of acral malignant melanoma in situ to add to the body of clinical knowledge.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PRAME IHC was performed in unequivocal cases of primary acral lentiginous melanoma in situ (ALMIS), subungual melanoma in situ (SMIS) and acral recurrent nevi as the control. PRAME tumour cell percentage positivity and intensity were expressed as categorised in a cumulative score by adding the quartile of positive tumour cells to intensity labelling. The final IHC expression was interpreted as negative (0\u20131), weak (2\u20133), moderate (4\u20135) or strong (6\u20137).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In 91 ALMIS patients, 32 cases (35.16%) were strong, 37 (40.66%) were moderate and 22 (24.18%) were weak. In 18 SMIS patients, strong positivity of PRAME was observed in 4 (22.22%) cases, moderate in 10 (55.56%) and weak in the remaining 4 (22.22%). No melanoma sample was negative for PRAME. By comparison, only 2 of the 40 acral recurrent nevi cases were positive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study supports the ancillary value of PRAME for diagnosing ALMIS and SMIS with high sensitivity and specificity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jcp-2022-208697","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T13:21:58Z","timestamp":1678195318000},"page":"417-420","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Analysis of PRAME immunocytochemistry in 109 acral malignant melanoma in situ"],"prefix":"10.1136","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-371X","authenticated-orcid":false,"given":"Qiu-ju","family":"Miao","sequence":"first","affiliation":[{"name":"Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Bao","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-fang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fujian Medical University cancer Hospital, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"2025092502111658000_77.6.417.1","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif"},{"key":"2025092502111658000_77.6.417.2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07985-6"},{"key":"2025092502111658000_77.6.417.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2016.09.016"},{"key":"2025092502111658000_77.6.417.4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jid.2018.10.041","article-title":"Noninvasive analysis of high-risk driver mutations and gene expression profiles in primary cutaneous melanoma","volume":"139","author":"Ferris","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2025092502111658000_77.6.417.5","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2025092502111658000_77.6.417.6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamadermatol.2017.0473","article-title":"Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy","volume":"153","author":"Ferris","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2025092502111658000_77.6.417.7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.pathol.2022.05.012","article-title":"Diagnostic utility of PRAME, p53 and 5-hmc immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics","volume":"54","author":"Rawson","year":"2022","journal-title":"Pathology"},{"key":"2025092502111658000_77.6.417.8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/PAS.0000000000001878","article-title":"Comparative analysis of prame expression in 127 acral and nail melanocytic lesions","volume":"46","author":"Santandrea","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"2025092502111658000_77.6.417.9","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/his.14312","article-title":"Prame immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna","volume":"78","author":"Gradecki","year":"2021","journal-title":"Histopathology"},{"key":"2025092502111658000_77.6.417.10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ajo.2018.07.045","article-title":"Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma","volume":"195","author":"Cai","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"2025092502111658000_77.6.417.11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","article-title":"Prame as a potential target for immunotherapy in metastatic uveal melanoma","volume":"135","author":"Gezgin","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2025092502111658000_77.6.417.12","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000068","article-title":"Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study","volume":"1","author":"Gutzmer","year":"2016","journal-title":"ESMO Open"},{"key":"2025092502111658000_77.6.417.13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/his.14814","article-title":"Prame is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics","volume":"82","author":"Chen","year":"2023","journal-title":"Histopathology"},{"key":"2025092502111658000_77.6.417.14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/cup.13876","article-title":"Prame expression in 155 cases of metastatic melanoma","volume":"48","author":"Gradecki","year":"2021","journal-title":"J Cutan Pathol"},{"key":"2025092502111658000_77.6.417.15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2021.11.002","article-title":"Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi","volume":"120","author":"Hu","year":"2022","journal-title":"Hum Pathol"},{"key":"2025092502111658000_77.6.417.16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/cup.14290","article-title":"Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions","volume":"49","author":"Rothrock","year":"2022","journal-title":"J Cutan Pathol"},{"key":"2025092502111658000_77.6.417.17","doi-asserted-by":"crossref","unstructured":"Gassenmaier M , Hahn M , Metzler G , et al . Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas. Cancers (Basel) 2021:13153864. doi:10.3390\/cancers13153864","DOI":"10.3390\/cancers13153864"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2022-208697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:11:39Z","timestamp":1758791499000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2022-208697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,17]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jcp-2022-208697"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2022-208697","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]}}}